New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 15, 2014
10:03 EDTACHNAchillion ACH-3102 data results 'impressive,' says Piper Jaffray
Piper Jaffray calls this morning's data for Achillion's ACH-3102 "impressive," saying the numbers validate the potential for combining ACH-3102 with a nuc. Piper still believes a potential acquirer could show interest in Achillion this fall given the relative near-term data releases. It has an Overweight rating on the stock with a $10 price target.
News For ACHN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
07:52 EDTACHNJ&J purchase of Alios an incremental negative for Achillion, says UBS
UBS views Johnson & Johnson's (JNJ) purchase of Alios as an incremental negative for Achillion (ACHN), as it implies there is now one less potential buyer of the company. However, the firm still thinks ACH-3422 will have considerable strategic value after data is reported and that other HCV players such as AbbVie (ABBV) and Bristol-Myers (BMY) are likely to be interested. UBS maintains its Buy rating and $15 price target on Achillion.
September 30, 2014
12:40 EDTACHNOn The Fly: Midday Wrap
Subscribe for More Information
12:03 EDTACHNAchillion sinks after Johnson & Johnson buys competitor
The shares of Achillion (ACHN), which has developed a treatment for hepatitis C based on a nucleotide and has been viewed as a potential takeover target by analysts previously, are falling after Johnson & Johnson (JNJ) announced this morning that it had agreed to acquire privately held Alios Biopharma. Alios has developed a number of nucleotide-based hepatitis C treatments, as well as an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus. WHAT'S NEW: Johnson & Johnson said that it had agreed to buy Alios for $1.75B. Alios has developed a number of nucleotides that could be used to treat hepatitis C virus, or HCV. Gilead's (GILD) popular HCV treatment Sovaldi is also a nucleotide and Achillion is developing its own HCV nucleotide treatment. According to The Street's Adam Feuerstein, Achillion's nucleotide is similar in structure to that of Alios. Johnson & Johnson had previously been rumored to be interested in buying Achillion, Feuerstein noted. WHAT'S NOTABLE: Johnson & Johnson said it was "excited" that its acquisition of Alios would enable it to "explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy." Novavax (NVAX) is also developing an RSV vaccine and Johnson & Johnson could have considered acquiring it before buying Alios, Feuerstein contended. PRICE ACTION: Near noon, Achillion fell 6% to $10.11, Gilead was down 0.6% to $106.84, Novavax dropped 1% to $4.27, and Johnson & Johnson rose 0.4% to just under $107 per share.
10:30 EDTACHNJ&J could have considered Novavax, Achillion instead of Alios, TheStreet says
Subscribe for More Information
September 26, 2014
18:50 EDTACHNRA Capital Management reduces passive stake in Achillion to 11.3% from 18.1%
10:18 EDTACHNOptions with decreasing implied volatility
Subscribe for More Information
September 25, 2014
15:38 EDTACHNAchillion CCO says NUC data won't be abstract at AASLD, Bloomberg reports
Subscribe for More Information
September 23, 2014
15:00 EDTACHNAchillion volatility elevated into expected release of viral data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use